Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Rating) CEO Robert J. Gould sold 6,766 shares of the stock in a transaction dated Friday, January 13th. The stock was sold at an average price of $15.00, for a total transaction of $101,490.00. Following the completion of the transaction, the chief executive officer now owns 499,864 shares of the company’s stock, valued at $7,497,960. The sale was disclosed in a document filed with the SEC, which is available through this link.
Fulcrum Therapeutics Price Performance
Shares of FULC traded down $0.27 on Friday, reaching $13.70. The company’s stock had a trading volume of 705,769 shares, compared to its average volume of 1,379,688. The stock has a market capitalization of $713.10 million, a P/E ratio of -5.35 and a beta of 1.90. The stock’s 50 day simple moving average is $7.28 and its two-hundred day simple moving average is $7.05. Fulcrum Therapeutics, Inc. has a 12-month low of $3.21 and a 12-month high of $24.79.
Fulcrum Therapeutics (NASDAQ:FULC – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.12. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $2.19 million. Fulcrum Therapeutics had a negative net margin of 1,000.65% and a negative return on equity of 54.55%. Analysts expect that Fulcrum Therapeutics, Inc. will post -2.45 earnings per share for the current year.
Hedge Funds Weigh In On Fulcrum Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Delphia USA Inc. purchased a new position in shares of Fulcrum Therapeutics in the second quarter worth approximately $58,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Fulcrum Therapeutics during the 2nd quarter valued at $83,000. SG Americas Securities LLC lifted its stake in shares of Fulcrum Therapeutics by 207.1% during the 2nd quarter. SG Americas Securities LLC now owns 13,173 shares of the company’s stock valued at $65,000 after buying an additional 8,884 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Fulcrum Therapeutics during the 1st quarter valued at $79,000. Finally, RTW Investments LP lifted its stake in shares of Fulcrum Therapeutics by 0.6% during the 3rd quarter. RTW Investments LP now owns 3,985,910 shares of the company’s stock valued at $32,246,000 after buying an additional 24,716 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on FULC. Stifel Nicolaus decreased their price target on shares of Fulcrum Therapeutics from $43.00 to $35.00 in a research note on Thursday, October 20th. Morgan Stanley increased their price target on shares of Fulcrum Therapeutics from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Monday, November 14th. The Goldman Sachs Group began coverage on shares of Fulcrum Therapeutics in a research note on Tuesday, November 15th. They set a “buy” rating and a $11.00 price objective for the company. Piper Sandler reduced their price objective on shares of Fulcrum Therapeutics from $42.00 to $18.00 in a research note on Tuesday, November 8th. Finally, Credit Suisse Group reduced their price objective on shares of Fulcrum Therapeutics from $22.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 9th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.71.
About Fulcrum Therapeutics
(Get Rating)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Further Reading
- Get a free copy of the StockNews.com research report on Fulcrum Therapeutics (FULC)
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
- Will Oil Stocks Once Again Lead The Market As Inflation Eases?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fulcrum Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Fulcrum Therapeutics wasn’t on the list.
While Fulcrum Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.
Wondering when you’ll finally be able to invest in SpaceX, StarLink or The Boring Company? Enter your email address below to learn when Elon Musk will let these companies finally IPO.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
